Home/Pipeline/AQU-118

AQU-118

Amyotrophic Lateral Sclerosis (ALS)

Phase 1Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 1

Status

Active

Company

Aquilus Pharmaceuticals

About Aquilus Pharmaceuticals

Aquilus Pharmaceuticals is a neurotherapeutics company advancing AQU-118, a novel, orally available matrix metalloproteinase (MMP) inhibitor, for the treatment of ALS. The company has secured significant non-dilutive grant funding from the ALS Association, NIH, and the Department of Defense, and has cleared its IND for a Phase 1 trial slated for early 2026. With a lean, experienced leadership team and prestigious academic collaborators, Aquilus is positioned to address a critical unmet need in a devastating disease with no approved MMP inhibitors on the market.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis (ALS)Neurodegenerative Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active